Anti-thymocyte globulin in haematology: Recent developments

Autor: Reinhold Munker, Jessica N. Cox, Gerhard C. Hildebrandt, Roger H. Herzig, Salahuddin Siddiqui, Senthilnathan Palaniyandi
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Swine
medicine.medical_treatment
severe aplastic anaemia
lcsh:Medicine
Graft vs Host Disease
Disease
Review Article
0302 clinical medicine
Recurrence
immunosuppressive effect
graft-versus-host disease
Medicine
030212 general & internal medicine
Hematology
biology
Goats
Anemia
Aplastic
Immunosuppression
General Medicine
Prognosis
surgical procedures
operative
Treatment Outcome
Immunotherapy
Rabbits
Immunosuppressive Agents
Risk
medicine.medical_specialty
Allogeneic transplantation
Globulin
030106 microbiology
General Biochemistry
Genetics and Molecular Biology
Anti-thymocyte globulin
03 medical and health sciences
Internal medicine
Animals
Humans
Horses
Antilymphocyte Serum
business.industry
lcsh:R
myelodysplastic syndrome
Immunoglobulin G
Myelodysplastic Syndromes
Immunology
biology.protein
Chronic gvhd
business
anti-thymocyte globulin - graft-versus-host disease - immunosuppressive effect - myelodysplastic syndrome - severe aplastic anaemia
Biomarkers
Zdroj: The Indian Journal of Medical Research
Indian Journal of Medical Research, Vol 150, Iss 3, Pp 221-227 (2019)
ISSN: 0971-5916
Popis: Anti-thymocyte globulin (ATG) is a polyclonal antiserum introduced into clinical medicine more than 30 years ago. It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and prophylaxis and treatment of graft-versus-host disease (GVHD) (after allogeneic transplantation). For aplastic anaemia, ATG from horses has been found to be superior to ATG from rabbits. In the situation of allogeneic transplantation, ATG lessens the risk of chronic GVHD but may not improve survival. There is current controversy regarding which patients benefit most from ATG and what the ideal dosage is. It is likely that in the coming years a more specific immunosuppressive will be developed that will minimize GVHD while maintaining the graft-versus-malignancy effect.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje